RPTX
NASDAQRepare Therapeutics Inc.
Price$2.63+0.73 (+38.32%)
2025-10-222026-01-27
News · 26 weeks290%
2025-12-142026-06-07
Mix090d
No activity.
Latest news
25 items- SECSEC Form EFFECT filed by Repare Therapeutics Inc.EFFECT - Repare Therapeutics Inc. (0001808158) (Filer)
- INSIDERSEC Form 4 filed by Large owner Bvf Partners L P/Il4 - Repare Therapeutics Inc. (0001808158) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13D/A filed by Repare Therapeutics Inc.SCHEDULE 13D/A - Repare Therapeutics Inc. (0001808158) (Subject)
- INSIDERDirector Rhoads Ann D returned 4,000 shares to the company, closing all direct ownership in the company (SEC Form 4)4 - Repare Therapeutics Inc. (0001808158) (Issuer)
- INSIDERDirector Schafer Carol returned 8,000 shares to the company, closing all direct ownership in the company (SEC Form 4)4 - Repare Therapeutics Inc. (0001808158) (Issuer)
- INSIDEREVP, CHIEF FINANCIAL OFFICER Forte Steve returned 56,786 shares to the company, closing all direct ownership in the company (SEC Form 4)4 - Repare Therapeutics Inc. (0001808158) (Issuer)
- INSIDERDirector Civik Thomas returned 7,500 shares to the company, closing all direct ownership in the company (SEC Form 4)4 - Repare Therapeutics Inc. (0001808158) (Issuer)
- INSIDERSVP, Finance and CAO Alves Sandra Isabelle Barros returned 31,622 shares to the company, closing all direct ownership in the company (SEC Form 4)4 - Repare Therapeutics Inc. (0001808158) (Issuer)
- SECSEC Form S-8 POS filed by Repare Therapeutics Inc.S-8 POS - Repare Therapeutics Inc. (0001808158) (Filer)
- SECSEC Form S-8 POS filed by Repare Therapeutics Inc.S-8 POS - Repare Therapeutics Inc. (0001808158) (Filer)
- SECSEC Form S-8 POS filed by Repare Therapeutics Inc.S-8 POS - Repare Therapeutics Inc. (0001808158) (Filer)
- SECSEC Form S-8 POS filed by Repare Therapeutics Inc.S-8 POS - Repare Therapeutics Inc. (0001808158) (Filer)
- SECSEC Form S-8 POS filed by Repare Therapeutics Inc.S-8 POS - Repare Therapeutics Inc. (0001808158) (Filer)
- SECSEC Form S-8 POS filed by Repare Therapeutics Inc.S-8 POS - Repare Therapeutics Inc. (0001808158) (Filer)
- SECSEC Form S-8 POS filed by Repare Therapeutics Inc.S-8 POS - Repare Therapeutics Inc. (0001808158) (Filer)
- SECSEC Form S-8 POS filed by Repare Therapeutics Inc.S-8 POS - Repare Therapeutics Inc. (0001808158) (Filer)
- SECSEC Form POS AM filed by Repare Therapeutics Inc.POS AM - Repare Therapeutics Inc. (0001808158) (Filer)
- SECRepare Therapeutics Inc. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control of Registrant, Other Events8-K - Repare Therapeutics Inc. (0001808158) (Filer)
- SECSEC Form 25-NSE filed by Repare Therapeutics Inc.25-NSE - Repare Therapeutics Inc. (0001808158) (Subject)
- SECSEC Form SCHEDULE 13G filed by Repare Therapeutics Inc.SCHEDULE 13G - Repare Therapeutics Inc. (0001808158) (Subject)
- SECRepare Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure8-K - Repare Therapeutics Inc. (0001808158) (Filer)
- PRRepare Shareholders Approve Acquisition by XenoTherapeutics, Inc.Repare Therapeutics Inc. ("Repare" or the "Company") (NASDAQ:RPTX), a clinical-stage precision oncology company, today announced that its Shareholders (as defined below) have approved the acquisition of all of the issued and outstanding common shares of the Company (the "Common Shares" and the holders of the Common Shares, the "Shareholders") by XenoTherapeutics, Inc. and Xeno Acquisition Corp. (jointly "Xeno") a non-profit biotechnology company, by way of a statutory plan of arrangement (the "Transaction" or the "Arrangement") at the special meeting of Shareholders held today (the "Meeting"). The special resolution approving the Arrangement was approved by: (i) 99.76% of the votes cast b
- SECSEC Form DEFA14A filed by Repare Therapeutics Inc.DEFA14A - Repare Therapeutics Inc. (0001808158) (Filer)
- SECRepare Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Entry into a Material Definitive Agreement8-K - Repare Therapeutics Inc. (0001808158) (Filer)
- PRRepare Therapeutics Announces Acquisition of Polθ ATPase Inhibitor, RP-3467, by Gilead Sciences for Up To $30 Million in Total ConsiderationRepare Therapeutics Inc. ("Repare" or the "Company") (NASDAQ:RPTX), a clinical-stage precision oncology company, today announced a definitive asset purchase agreement for Gilead Sciences, Inc. to acquire Repare's polymerase theta (Polθ) ATPase inhibitor, RP-3467 (the "Gilead Agreement"). "We are pleased to announce this transaction which combines Gilead's leading expertise in oncology research and development with RP-3467, a potential best-in-class Polθ ATPase inhibitor," said Steve Forte, President, Chief Executive Officer and Chief Financial Officer of Repare. "This marks the third and most significant portfolio transaction for Repare this year." Under the terms of the Gilead Agreemen
RPTX FAQ
7 questionsWhat does Repare Therapeutics Inc. do?
Repare Therapeutics Inc., a precision oncology company, discovers and develops novel therapeutics by using its synthetic lethality approach in Canada and the United States. The company uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. Its lead product candidate is RP-3500, an oral small-molecule inhibitor for the treatment of solid tumors with specific DNA damage repair-related genomic alterations. It is also developing RP-6306, a...Where does RPTX stock trade?
Repare Therapeutics Inc. (RPTX) is listed on NASDAQ.What sector and industry is RPTX in?
Repare Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Repare Therapeutics Inc. go public?
Repare Therapeutics Inc. (RPTX) completed its IPO in 2020.What are analysts saying about RPTX?
Repare Therapeutics Inc. has had 8 recent analyst actions on file. The most recent action was from Stifel: Buy with a $1600.00 price target on 2023-06-09. Recent price targets range from $1100.00 to $4800.00.What companies are similar to RPTX?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare RPTX side-by-side with any of them on Quantisnow.How can I track RPTX on Quantisnow?
Quantisnow aggregates Repare Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow RPTX to receive live email and push alerts on every new disclosure.